WHO vaccine-preventable diseases: monitoring system. 2018 global summary

Last updated 1-Jun.-2018 (data as of 25-May-2018)
Next overall update Mid-July 2018
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 1 Infant (under 12 months) mortality rate: 292
GDP / capita (US$): 1 Child (under 5 years) mortality rate: 352

Population data in thousands3

  2017  2016  2015  2014  2013  2000  1990  1980 
Total population 53  53  53  53  53  52  47  31 
Births
Surviving infants
Pop. less than 5 years
Pop. less than 15 years 15  16  16  16  16  18  18  12 
Female 15-49 years 13  13  13  13  13  14  12 

Number of reported cases

(Click for retrospective incidence data for Marshall Islands (the))
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  14 
Mumps
ChartChart
 
Pertussis
ChartChart
 
Polio*
ChartChart
 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Marshall Islands (the))
Vaccine year result method % card seen                                                
BCG 2006  70  DHS   75  96  94  99*  89  93  89  49 
DTP1 2006  71  DHS   75  97  87  95  97  73  23 
DTP3 2006  48  DHS   75  80  71  85  78  36  39  92 
DTP4          55  49  75  53 
IPV1          96  95  95 
HepB_BD          86  89  99*  76  70  99* 
HepB3          82  73  85  79  41  38 
Hib3          65  58  70  65  21  45 
JapEnc          13 
MCV1          83  75  75  79  70  94  52 
MCV2          62  49  70  53  42 
MenA         
PCV1          96  94  95  70  72 
PCV2          87  82  90  46  43 
PCV3          72  65  75  29  22 
Pol3 2006  46  DHS   75  79  69  85  77  36  36  89 
Rota1          78  73  95  65  71 
RotaC          46  38  90  44  45 
RCV1          83  75  75  79  70 
TT2plus 2006  20  DHS   75  29  57  95  53 
PAB          94 
VAD1          13  95 
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Marshall Islands (the))
BCG
ChartChart
  99  99  89  93  89  49 
DTP1
ChartChart
  95  95  97  97  64  97 
DTP3
ChartChart
  85  85  78  79  39  92 
HepB3
ChartChart
  85  85  79  80  38  10 
HepB_BD
ChartChart
  99  99  76  81  99 
Hib3
ChartChart
  70  70  65  66  45 
MCV1
ChartChart
  75  75  79  79  94  52 
MCV2
ChartChart
  70  70  53  56 
PCV3
ChartChart
  75  75  29  38 
Pol3
ChartChart
  85  85  77  79  36  89 
RCV1
ChartChart
  75  75  79  79  94 
RotaC
ChartChart
  90  90  44  52 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2017 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTaPHepBIPV 2, 4, 6, 12 months; 4-6 years; Yes
DTaPHepIPV 2, 4, 6 months; Yes
DTaPHibIPV 2, 4, 12 months; Yes
DTaPIPV 4-5 years; 1
HepB_Pediatric birth; 2, 6, months; Yes
Hib 2, 4, 12 months; Yes
HPV 11-12 years; Yes females
Influenza_Adult >=50 years; Yes and adults with chronic illness, pregnant women, health care workers
Influenza_Pediatric 6 months-4 years; Yes and children with chronic illness
IPV 2, 4, 6 months; 4-6 years; Yes
MenC_conj 11-12 years; Yes
MMR 12, 13 months; Yes
Pneumo_conj 2, 4, 6, 12 months; Yes
Rotavirus 2, 4, 6, 12 months; Yes
Tdap 11-12 years; Yes

Immunizaton indicators

Indicator Expected answer 2017  2016  2015  2014  2013  2012  2011 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR   Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number   2016-2018  2016-2018  2008-2014  2008-2014  2008-2012  2012-2014 
Nº of districts with microplans that include activities to raise immunization coverage number      

System performance

Total Nº districts in country number  
Nº districts with DTP3 coverage >=80% number    
% of districts with DTP3 coverage >=80% From 0 to 100%     33    100  100  33 
Nº districts with measles (MCV1) coverage >=95% number      
% of districts with MCV1 coverage >=95% From 0 to 100%     33    100 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND     No  Yes  Yes  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR     Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%     100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR   No  No        No 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2018
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.